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Chairmen’s introduction
In March 2005 a unique meeting was held in Milan,
Italy, which brought together international experts
from three specialities – gastroenterology, cardiology
and rheumatology. The aim of this meeting was to
provide insight and guidance for clinicians across the
globe regarding the balance of risks and benefits when
prescribing non-steroidal anti-inflammatory drug
(NSAID) treatment, particularly in patients at risk of
gastrointestinal (GI) damage or those with cardiovas-
cular (CV) risk factors.
Current management of a patient who requires NSAID
therapy, such as those with rheumatoid arthritis,
osteoarthritis or ankylosing spondylitis, is far from
simple, in particular with regard to the choice of an
effective, low risk therapeutic agent.
In September 2004, the pharmaceutical manufacturer
Merck voluntarily withdrew rofecoxib, a cyclo-
oxygenase-2 (COX-2) selective inhibitor, from the
market. This decision was made after a chemopreven-
tion study revealed that after 18 months of therapy,
subjects receiving rofecoxib had roughly twice the rate
of myocardial infarction and stroke when compared
with the rate seen in placebo controls.1 On 07 April
2005, the US Food and Drug Administration requested
that Pfizer remove valdecoxib from the market after
concluding its benefits did not outweigh its comprehen-
sive safety profile.2 COX-2 selective inhibitors, which
until these recent events represented around one-third
of all NSAID prescriptions in the USA, were originally
developed to reduce the risk of GI adverse events
commonly seen with NSAIDs, while still providing
comparable symptom relief.
The withdrawal of two commonly prescribed COX-2
inhibitors used by millions of patients worldwide has
prompted a re-evaluation by regulatory agencies of the
safety of the whole class of COX-2 inhibitors. Prescribing
clinicians are now weighing up the known risks of
COX-2 inhibitors with the benefits of pain relief in
considering whether this class of agents is appropriate
for their patients who need anti-inflammatory therapy,
especially those with underlying CV risk.
The discussions and recommendations made at this
meeting, and summarized here, are intended to help and
guide physicians in clinical practice when prescribing
NSAIDs, including COX-2 inhibitors, for their patients,
many of whom may also be taking low-dose aspirin for
prophylaxis against cardiovascular events.
The views of the expert panel of rheumatologists,
cardiologists and gastroenterologists from Europe, the
USA and Asia were each considered in turn, taking
into account existing international treatment guide-
lines, GI and CV risk definitions, and recent recom-
mendations. The whole panel then debated these
overlapping viewpoints in the light of the available
evidence about COX-2 inhibitors, and developed rec-
ommendations for patient treatment with NSAIDs,
dependent on their level of GI and/or CV risk. Overall
it was concluded that in many patients traditional,
non-selective NSAIDs may be used as an alternative to
COX-2 inhibitors, however for those patients at risk of
GI damage or those also taking aspirin, a gastropro-
tective agent, such as a proton-pump inhibitor, should
also be prescribed.
We would like to thank the entire faculty involved in
this meeting for their active participation and valuable
input into the discussions and recommendations.
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